Clinical trials: Insufficient Metabolic Control
Diabetes Mellitus, Type 2
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.
- Trial name
- NCT00106704
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30 weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual monotherapies of pioglitazone (15 mg, 30…
- Trial name
- NCT01183013
- Testing
- Pioglitazone 15 mg, Pioglitazone 45 mg, Pioglitazone 30 mg
- Where
- 132 sites in United States, Estonia and 4 more
- Volunteers
- 936 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Linagliptin as Add on to Basal Insulin in the Elderly
To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older…
- Trial name
- NCT02240680
- Testing
- linagliptin
- Where
- 145 sites in United States, Australia and 15 more
- Volunteers
- 302 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to…
- Trial name
- NCT02551874
- Testing
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin
- Where
- 40 sites in United States, Czechia and 8 more
- Volunteers
- 650 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
The purpose of this study was to compare effect of Saxagliptin as add-on to Metformin on 24-hour mean weighted glucose (MWG) to the effect of uptitrating Metformin in subjects with T2DM inadequately controlled on metformin alone.
- Trial name
- NCT00918138
- Testing
- Saxagliptin, Metformin XR
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 219 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in addition to diet and exercise therapy.
- Trial name
- NCT02906709
- Testing
- Omarigliptin, Insulin
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise.
- Trial name
- NCT01958671
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg, Metformin
- Volunteers
- 461 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJ-30001 and CJ-30002 in Type 2 Diabetes Mellitus Patients
The aim of this study is to evaluate the efficacy and safety fo CJ-30001/CJ-30002.
- Trial name
- NCT01370707
- Testing
- Metformin, CJ-30001/CJ-30002
- Where
- 21 sites in South Korea
- Volunteers
- 187 people
- Sponsor
- HK inno.N Corporation
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in…
- Trial name
- NCT03467932
- Testing
- Cohort A: ORMD-0801, Cohort B: ORMD-0801
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- Oramed, Ltd.
Hypercholesterolemia
A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins
To investigate the efficacy and safety of Pemafibrate 0.2 mg/day or 0.4 mg/day for 12 weeks in patients with hypercholesterolemia and inadequate response to statins, using placebo as a control.
- Trial name
- NCT07634484
- Testing
- Pemafibrate 0.2 mg/day, Pemafibrate 0.4 mg/day
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Kowa Company, Ltd.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.
- Trial name
- CMAS (NCT02173457)
- Testing
- Chiglitazar, Sitagliptin
- Where
- 37 sites in China
- Volunteers
- 740 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and Nateglinide inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01316107
- Testing
- ipragliflozin, nateglinide
- Where
- 4 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Astellas Pharma Inc
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise.
- Trial name
- NCT07743983
- Testing
- BGM0504, semaglutide
- Where
- China
- Volunteers
- 372 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide…
- Trial name
- UNIGUIDE-2 (NCT07653477)
- Testing
- UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group
- Where
- China
- Volunteers
- 956 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Trial name
- NCT05666128
- Testing
- HD-6277
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Hyundai Pharm
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin
The purpose of this study is to assess the effect of canagliflozin (JNJ-28431754) compared to placebo in the treatment of participants with Type 2 Diabetes Mellitus (T2DM), who have inadequate glycemic control on maximally or…
- Trial name
- NCT02025907
- Testing
- Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
- Trial name
- NCT00147719
- Testing
- Colesevelam hydrochloride
- Where
- 48 sites in United States, Mexico and 1 more
- Volunteers
- 300 people
- Sponsor
- Daiichi Sankyo